Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•16/11/2026•16:05 ET
0
Key Highlights
- ➤Royalty agreement maximum payments cut from $125 million to $65 million
- ➤FG-3246 and FG-3180 discontinued after insufficient Phase 2 efficacy
- ➤Roxadustat Phase 3 LR-MDS trial planned for 1Q 2027, funding dependent
- ➤Third-quarter revenue $1.8 million, up from $1.1 million year over year
- ➤Cash, investments, and receivables totaled $44.1 million; runway extends into 2028
Expert Statements
Thane Wettig, Chief Executive Officer of Kyntra Bio
“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial”
Thane Wettig, Chief Executive Officer of Kyntra Bio
“We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial.”
Thane Wettig, Chief Executive Officer of Kyntra Bio
“The unmet medical need and corresponding multi-billion-dollar commercial opportunity in LR-MDS is significant.”
Thane Wettig, Chief Executive Officer of Kyntra Bio
“Subject to the execution of either a strategic partnership or an external capital raise, we plan on initiating the pivotal Phase 3 trial in the first quarter of 2027.”
* Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining
* Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in LR-MDS patients with high transfusion burden (HTB) planned in 1Q 2027, subject to the execution of either a strategic partnership or an external capital raise
Get started
Create a free account to read the full story.
